Titre
Tumor antigens recognized by T lymphocytes
Type
synthèse (review)
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Boon, T.
Auteure/Auteur
Cerottini, J. C.
Auteure/Auteur
Van den Eynde, B.
Auteure/Auteur
van der Bruggen, P.
Auteure/Auteur
Van Pel, A.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
0732-0582
Statut éditorial
Publié
Date de publication
1994
Volume
12
Première page
337
Dernière page/numéro d’article
65
Notes
Journal Article
Review
Review
Résumé
Transplantation experiments have demonstrated that most mouse tumors express antigens that can constitute targets for rejection responses mediated by syngeneic T lymphocytes. For human tumors, autologous cultures mixing tumor cells and blood lymphocytes or tumor-infiltrating lymphocytes have produced CD8+ and CD4+ cytolytic T cell (CTL) clones that recognize tumor cells specifically. Attempts to identify the target antigens by biochemical fractionation of tumor cells up to now have failed, with the important exception of the identification of underglycosylated mucins present on breast and pancreatic carcinomas. Gene transfection approaches have proved more successful. A gene family named MAGE codes for antigens recognized by autologous CTL on a melanoma tumor. These genes are not expressed in normal tissues except for testis. They are expressed in many tumors of several histological types. Differentiation antigens coded by genes such as tyrosinase are also recognized on human melanoma by autologous CTL. The identification of human tumor rejection antigens opens new possibilities for systematic approaches to the specific immune therapy of cancer.
Sujets
PID Serval
serval:BIB_FF5B5CF5A462
PMID
Date de création
2008-01-28T10:14:52.013Z
Date de création dans IRIS
2025-05-21T05:54:08Z